Next Article in Journal / Special Issue
Mouse Models of Gastric Cancer
Previous Article in Journal / Special Issue
Gastric Cancer: Current Status of Diagnosis and Treatment
Open AccessReview

Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy

Medical Oncology Department, The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Castle Lane East, BH7 7DW Bournemouth, Dorset, UK
*
Author to whom correspondence should be addressed.
Cancers 2013, 5(1), 64-91; https://doi.org/10.3390/cancers5010064
Received: 3 December 2012 / Revised: 1 January 2013 / Accepted: 14 January 2013 / Published: 21 January 2013
(This article belongs to the Special Issue Gastric Cancer)
Gastric cancer (GC) represents a major cancer burden worldwide, and remains the second leading cause of cancer-related death. Due to its insidious nature, presentation is usually late and often carries a poor prognosis. Despite having improved treatment modalities over the last decade, for most patients only modest improvements have been seen in overall survival. Recent progress in understanding the molecular biology of GC and its signaling pathways, offers the hope of clinically significant promising advances for selected groups of patients. Patients with Her-2 overexpression or amplification have experienced benefit from the integration of monoclonal antibodies such as trastuzumab to the standard chemotherapy. Additionally, drugs targeting angiogenesis (bevacizumab, sorafenib, sunitinib) are under investigation and other targeted agents such as mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors are in preclinical or early clinical development. Patient selection and the development of reliable biomarkers to accurately select patients most likely to benefit from these tailored therapies is now key. Future trials should focus on these advances to optimize the treatment for GC patients. This article will review recent progress and current status of targeted agents in GC. View Full-Text
Keywords: gastric cancer; molecular targeted agents; monoclonal antibody; tyrosine kinase inhibitor gastric cancer; molecular targeted agents; monoclonal antibody; tyrosine kinase inhibitor
MDPI and ACS Style

Cidon, E.U.; Ellis, S.G.; Inam, Y.; Adeleke, S.; Zarif, S.; Geldart, T. Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy. Cancers 2013, 5, 64-91.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop